NCT00002620 is a Phase 3 clinical trial of carmustine in Brain and Central Nervous System Tumors, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.

Who is sponsoring NCT00002620?

NCT00002620 is sponsored by European Organisation for Research and Treatment of Cancer - EORTC.

What drugs are being tested in NCT00002620?

Interventions in NCT00002620: carmustine, chemotherapy, mitolactol, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy.

What condition does NCT00002620 study?

NCT00002620 studies Brain and Central Nervous System Tumors.

Is NCT00002620 still recruiting?

NCT00002620 is currently completed. Last updated 29 June 2012.

Last reviewed 2012-06-29 · How we verify

NCT00002620

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY

Completed Phase 3 Last updated 29 June 2012

What this trial tests

Phase 3 trial testing carmustine in Brain and Central Nervous System Tumors in 212 participants. Completed.

Timeline

1 November 1994

Primary endpoint
1 June 2000

Quick facts

Lead sponsor	European Organisation for Research and Treatment of Cancer - EORTC
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Primary purpose	treatment
Enrollment	212
Start date	1 November 1994
Primary completion	1 June 2000
Sites	14 locations across Austria, Belgium, Germany, Italy, Netherlands, Portugal, Switzerland, United Kingdom

Drugs / interventions tested

carmustine (CARMUSTINE) — full drug profile →
chemotherapy (chemotherapy) — full drug profile →
mitolactol (MITOLACTOL) — full drug profile →
low-LET cobalt-60 gamma ray therapy
low-LET photon therapy

Conditions studied

Brain and Central Nervous System Tumors — all drugs for Brain and Central Nervous System Tumors →

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC — full company profile →

Who can join

16 and older, any sex, with Brain and Central Nervous System Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for patients with anaplastic astrocytomas. PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy in treating patients with anaplastic astrocytomas.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of carmustine

Trials testing the same drug.

NCT05052957 — hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) · Phase 2 · recruiting
NCT01476839 — Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients W · Phase 1 · completed
NCT00695409 — Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma · Phase 2 · completed
NCT00536601 — High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Pa · NA · completed
NCT00345865 — Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma · Phase 2 · completed

Other recruiting trials for Brain and Central Nervous System Tumors

Currently open trials in the same condition.

NCT00978458 — Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma · Phase 3 · active not recruiting

Other European Organisation for Research and Treatment of Cancer - EORTC trials

Trials by the same sponsor.

NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
NCT06978062 — Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment · Phase 1 · not yet recruiting
NCT06809322 — Vorasidenib Maintenance for IDH Mutant Astrocytoma · Phase 3 · recruiting
NCT06990061 — Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, · NA · not yet recruiting
NCT06783348 — Radiopharmaceutical Treatment of Advanced Kidney Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00002620 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by European Organisation for Research and Treatment of Cancer - EORTC
Last refreshed: 29 June 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00002620.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing